Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior

Schizophrenia Research

Volumn 131, Issue 1-3, 2011, Pages 58-62

  Correll, Christoph U ^a,b,c   Shaikh, Ladan ^a   Gallego, Juan A ^a   Nachbar, Jeffrey ^a   Olshanskiy, Vladimir ^a   Kishimoto, Taishiro ^a   Kane, John M ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Antipsychotics; Attitudes; Polypharmacy; Prescriber; Reasons; Schizophrenia

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; QUETIAPINE;

ARTICLE; DRUG HYPERSENSITIVITY; HUMAN; MONOTHERAPY; MORTALITY; PHYSICIAN ATTITUDE; POLYPHARMACY; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; RISK FACTOR; SCHIZOPHRENIA; SEMI STRUCTURED INTERVIEW; TEACHING HOSPITAL;

ANTIPSYCHOTIC AGENTS; ATTITUDE; FEMALE; HEALTH SURVEYS; HUMANS; INTERVIEW, PSYCHOLOGICAL; KNOWLEDGE; MALE; MENTAL DISORDERS; MULTIVARIATE ANALYSIS; PHYSICIANS; POLYPHARMACY; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 80051796537     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.02.016     Document Type: Article

References (36)

1. Baandrup L., Allerup P., Nordentoft M., Lublin H., Glenthoj B.Y. Exploring regional variation in antipsychotic coprescribing practice: a danish questionnaire survey. J. Clin. Psychiatry 2010, 71(11):1457-1464. Nov.
2. Barbui C., Signoretti A., Mulè S., Boso M., Cipriani A. Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?. Schizophr. Bull. 2009, 35(2):458-468. Mar.
3. Biancosino B., Barbui C., Marmai L., Dona S., Grassi L. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int. Clin. Psychopharmacol. 2005, 20(6):305-309. Nov.
4. Centorrino F., Goren J.L., Hennen J., Salvatore P., Kelleher J.P., Baldessarini R.J. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am. J. Psychiatry 2004, 161(4):700-706. Apr.
5. Chang J.S., Ahn Y.M., Park H.J., Lee K.Y., Kim S.H., Kang U.G., Kim Y.S. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2008, 69(5):720-731. May.
6. Correll C.U. Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment?. J. Clin. Psychiatry 2008, 69(4):674-675. Apr.
7. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr. Res. 2007, 89(1-3):91-100. Jan.
8. Correll C.U., Rummel-Kluge C., Corves C., Kane J.M., Leucht S. Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophr. Bull. 2009, 35(2):443-457. Mar.
9. Faries D., Ascher-Svanum H., Zhu B., Correll C., Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005, 5:26. May 27.
10. Fleischhacker W.W., Heikkinen M.E., Olié J.P., Landsberg W., Dewaele P., McQuade R.D., Loze J.Y., Hennicken D., Kerselaers W. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 2010, 13(8):1115-1125. Sep.
11. Ganguly R., Kotzan J.A., Miller L.S., Kennedy K., Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J. Clin. Psychiatry 2004, 65(10):1377-1388. Oct.
12. Gilmer T.P., Dolder C.R., Folsom D.P., Mastin W., Jeste D.V. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr. Serv. 2007, 58(7):1007-1010. Jul.
13. Ito H., Koyama A., Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br. J. Psychiatry 2005, 187:243-247. Sep.
14. Jaffe A.B., Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol. Drug Saf. 2003, 12(1):41-48. Jan-Feb.
15. Joukamaa M., Heliovaara M., Knekt P., Aromaa A., Raitasalo R., Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br. J. Psychiatry 2006, 188:122-127. Feb.
16. Kane J.M., Correll C.U. Past and present progress in the pharmacologic treatment of schizophrenia. J. Clin. Psychiatry 2010, 71(9):1115-1124. Sep.
17. Kessing L.V., Thomsen A.F., Mogensen U.B., Andersen P.K. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br. J. Psychiatry 2010, 197(4):266-271. Oct.
18. McCue R.E., Waheed R., Urcuyo L. Polypharmacy in patients with schizophrenia. J. Clin. Psychiatry 2003, 64(9):984-989. Sep.
19. Miller A.L., Craig C.S. Combination antipsychotics: pros, cons, and questions. Schizophr. Bull. 2002, 28(1):105-109.
20. Mojtabai R., Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch. Gen. Psychiatry 2010, 67(1):26-36. Jan.
21. Nielsen J., le Quach P., Emborg C., Foldager L., Correll C.U. 10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr. Scand. 2010, 122(5):356-366. Nov.
22. Pandurangi A.K., Dalkilic A. Polypharmacy with second-generation antipsychotics: a review of evidence. J. Psychiatr. Pract. 2008, 14(6):345-367. Nov.
23. Paton C., Whittington C., Barnes T.R. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J. Clin. Psychopharmacol. 2007, 27(2):198-204. Apr.
24. Procyshyn R.M., Honer W.G., Wu T.K., Ko R.W., McIsaac S.A., Young A.H., Johnson J.L., Barr A.M. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J. Clin. Psychiatry 2010, 71(5):566-573. May.
25. Rupnow M.F., Greenspan A., Gharabawi G.M., Kosik-Gonzalez C., Zhu Y., Stahl S.M. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr. Med. Res. Opin. 2007, 23(11):2815-2822. Nov.
26. Sernyak M.J., Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J. Clin. Psychiatry 2004, 65(12):1597-1600. Dec.
27. Stahl S.M. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?. J. Clin. Psychiatry 1999, 60(7):425-426. Jul.
28. Stahl S.M. Antipsychotic polypharmacy: evidence based or eminence based?. Acta Psychiatr. Scand. 2002, 106(5):321-322. Nov.
29. Stahl S.M. Antipsychotic polypharmacy: squandering precious resources?. J. Clin. Psychiatry 2002, 63(2):93-94. Feb.
30. Stahl S.M., Grady M.M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr. Med. Chem. 2004, 11(3):313-327. Feb.
31. Tapp A., Wood A.E., Secrest L., Erdmann J., Cubberley L., Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr. Serv. 2003, 54(1):55-59. Jan.
32. Tranulis C., Skalli L., Lalonde P., Nicole L., Stip E. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf. 2008, 31(1):7-20.
33. Valuck R.J., Morrato E.H., Dodd S., Oderda G., Haxby D.G. Medicaid Pharmacotherapy Research Consortium. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs. Curr. Med. Res. Opin. 2007, 23(10):2567-2576. Oct.
34. Waddington J.L., Youssef H.A., Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br. J. Psychiatry 1998, 173:325-329. Oct.
35. Zhu B., Ascher-Svanum H., Faries D.E., Correll C.U., Kane J.M. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry 2008, 8:19. Apr 4.
36. Zink M., Englisch S., Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr. Opin. Psychiatry 2010, 23(2):103-111. Mar.